Severity
Moderate
FDA Drug recall · Reported February 5, 2020
Subpotent: Out of specification for assay at the 12-month time point.
Pharmaceutical Associates Inc recalled Nystatin Oral Suspension, USP 100,000 units per mL Cherry/Peppermint Flavor, 16 fl oz (47… - a moderate-severity action.
Nystatin Oral Suspension, USP 100,000 units per mL Cherry/Peppermint Flavor, 16 fl oz (47… was recalled by Pharmaceutical Associates Inc in February 5, 2020. Reason: Subpotent: Out of specification for assay at the 12-month time point.. Check the official notice for the remedy. Verify recall #D-0824-2020 with the FDA Drug before acting.
The recall
Pharmaceutical Associates Inc issued this moderate-severity FDA Drug recall-Subpotent: Out of specification for assay at the 12-month time point..
Sourced from official FDA Drug enforcement records. Verify recall #D-0824-2020 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0824-2020) was formally reported on February 5, 2020, with the manufacturer initiating the action on January 14, 2020. It is classified under Moderate severity (Class II), with a current status of Terminated. Pharmaceutical Associates Inc is listed as the recalling firm, operating out of Greenville, SC. Federal records list the affected scope as 6288 16 oz bottles.
The documented reason for this recall is: Subpotent: Out of specification for assay at the 12-month time point. Distribution data in the federal record shows the product reached: Distributed Nationwide in the US. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
6288 16 oz bottles
Related Recalls
6
5 from same agency
Nystatin Oral Suspension, USP 100,000 units per mL Cherry/Peppermint Flavor, 16 fl oz (473 mL) Rx Only, pai, Pharmaceutical Associates, Inc. Greenville, SC 29605. NDC 0121-0810-16
Subpotent: Out of specification for assay at the 12-month time point.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0824-2020 |
| Date reported | February 5, 2020 |
| Date initiated | January 14, 2020 |
| Recalling firm | Pharmaceutical Associates Inc |
| Firm location | Greenville, SC |
| Affected scope | 6288 16 oz bottles |
| Distribution | Distributed Nationwide in the US |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported February 5, 2020. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.